Reader Response: Practice Current: How do you treat neuromyelitis optica?
Citation Manager Formats
Make Comment
See Comments

A few lingering questions on this topic.1
I find it strange that Ocrevus, a CD20 blocker, is akin to Rituxan but not even on the map for treatment of neuromyelitis optica spectrum disorder (NMOSD), although Rituxan has been extensively used for this disease.
What is double-negative (Ab) NMOSD? Does it exist?
One hopes that there are better guidelines for monitoring CD19 cell counts (how frequent, endpoints, pitfalls, variations between end-stage disease and early-onset disease, if any).
Pregnancy vs disease-modifying drugs in NMOSD is characterized by paucity of data. We need better data. Also, data collected will hopefully be openly shared among researchers so that there are many minds working on the same topic instead of a select few.
Footnotes
Author disclosures are available upon request (ncpjournal{at}neurology.org).
- © 2018 American Academy of Neurology
References
- 1.↵
- Ganesh A
The Nerve!: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Dr. Nicole Sur and Dr. Mausaminben Hathidara
► Watch
Alert Me
Recommended articles
-
Article
Pregnancy in Patients With AQP4-Ab, MOG-Ab, or Double-Negative Neuromyelitis Optica DisorderNicolas Collongues, Cecilia Alves Do Rego, Bertrand Bourre et al.Neurology, February 24, 2021 -
Articles
AQP4 antibody–positive Thai casesClinical features and diagnostic problemsS. Siritho, I. Nakashima, T. Takahashi et al.Neurology, August 03, 2011 -
Article
Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disordersDouglas Kazutoshi Sato, Dagoberto Callegaro, Marco Aurelio Lana-Peixoto et al.Neurology, January 10, 2014 -
Article
Aquaporin-4 antibody–positive cases beyond current diagnostic criteria for NMO spectrum disordersDouglas Kazutoshi Sato, Ichiro Nakashima, Toshiyuki Takahashi et al.Neurology, May 15, 2013